Sign in
TerminatedPhase 2

Ketamine for OUD and Suicidal Ideation in the ED

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
4 people enrolled
Started
14 Jun 2024
Ended
31 Mar 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ketamine
  • Saline Solution
Record updated
8 April 2025
Why it stopped
Low recruitment numbers and study funding will be closing shortly.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Other criteria

  • Inclusion/Exclusion Criteria:
  • To be eligible, individuals must be/have:
  • English speaking adults aged 18 and above
  • Diagnosed with DSM5 opioid use disorder, moderate or severe, or clinically suspected opioid use disorder
  • Endorsing suicidal ideation sufficiently severe to meet criteria for referral to an inpatient psychiatric facility or a crisis stabilization unit
  • Any prior history of an opioid overdose
  • Medically cleared; Individuals with any of the following will be excluded:
  • Any psychotic disorder or active homicidally
  • Inability to perform consent due to impaired mental status
  • Current substance intoxication or current (or within the past 1-month) mania, hypomania, mixed-episode, or psychosis
  • Systolic blood pressure persistently elevated above 160mmHg, diastolic blood pressure greater than 100 mmHg, or heart rate >100bmp, in the ED
  • Clinical Opioid Withdrawal Scale (COWS) score of 12 or greater
  • History of hypersensitivity to ketamine, or experience of emergence reaction
  • History of hypersensitivity to ondansetron or concurrently using apomorphine
  • History of any illicit or recreational use of ketamine in the past 12 months
  • Receipt of ketamine treatment for depression in the past 3 months
  • History of DSM5 hallucinogen use disorder, intracranial mass or bleed, porphyria, thyrotoxicosis, seizure disorder other than from alcohol withdrawal, liver cirrhosis, or sleep apnea
  • Cardiac or EKG abnormalities based on history, physical examination or the baseline EKG
  • History within 6 months of thoracic surgery, lung cancer, head trauma, stroke, or myocardial infarction
  • Liver dysfunction with LFTs >3x upper normal limit
  • Current use of medications with known drug-drug interactions with ketamine (i.e., St. John's Wort, theophylline, opioid analgesics other than buprenorphine and methadone for the treatment OUD, Central Nervous System (CNS) depressants other than benzodiazepines or phenobarbital)
  • Pregnant
  • Patients who are breastfeeding
  • ASA class 3 or greater or documented history of difficult airway in HER
  • Active exacerbation of COPD or asthma
  • Currently participating or anticipated to participate in a concurrent investigational clinical trial
  • High risk for adverse emotional or behavioral reaction based on the opinion of the study investigators, including evidence of a personality disorder

Where in United States

  • Brigham and Women's HospitalBoston, United States

About the trial

What the trial wants to find out

This is a pilot, double-blind, placebo-controlled randomized clinical trial of individuals with opioid use disorder (OUD) with suicidal ideation in the emergency department (ED) to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25). The primary aim is to evaluate the safety of the ketamine treatment. The secondary aim is to determine the preliminary efficacy of opioid- and suicide-related outcomes.

The 2 groups in the trial

  • KetamineTreatment being tested

    This arm will receive ketamine (n=25)

  • Saline PlaceboPlacebo, for comparison

    This arm will receive the saline placebo (n=25)

    Treatment: Saline Solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ketamine for the Treatment for Opioid Use Disorder and Suicidal Ideation in the Emergency Department
Record updated
8 April 2025